Occludin S408 phosphorylation regulates tight junction protein interactions and barrier function by Raleigh, David R. et al.
JCB: Article
The Rockefeller University Press    $30.00
J. Cell Biol. Vol. 193 No. 3  565–582
www.jcb.org/cgi/doi/10.1083/jcb.201010065 JCB 565
D.M. Boe, D. Yu, and C.R. Weber contributed equally to this paper.
Correspondence to Jerrold R. Turner: jturner@bsd.uchicago.edu; or Le Shen: 
leshen@uchicago.edu
Abbreviations used in this paper: DMAT, 2-dimethylamino-4,5,6,7-tetrabromo-
1H-benzimidazole; EGFP, enhanced green fluorescent protein; FITC, fluorescein 
isothiocyanate; KD, knockdown; mRFP1, monomeric red fluorescent protein 1; 
TAMP,  TJ-associated  MARVEL  protein;  TBCA,  tetrabromocinnamic  acid;  TER, 
transepithelial electrical resistance; TJ, tight junction.
Introduction
The tight junction (TJ) is a complex of transmembrane and 
peripheral  membrane  proteins  that  define  the  paracellular 
barrier (Mitic and Anderson, 1998; Tsukita and Furuse, 2002; 
Anderson and Van Itallie, 2009). Although binding of clau-
dins to ZO-1 or ZO-2 is critical for TJ assembly (McNeil   
et al., 2006; Shin and Margolis, 2006; Umeda et al., 2006), 
the contributions of these and other interprotein interactions 
to barrier regulation in living cells are poorly understood. 
Recent  analyses  using  FRAP  and  related  techniques  have 
demonstrated that, despite numerous physical links between 
TJ proteins, the molecular structure of the steady-state TJ is 
highly dynamic and TJ protein complexes undergo continu-
ous remodeling with unique kinetics and varied mechanisms 
for each of the TJ complex components (Shen et al., 2008). 
We therefore hypothesized that modification of interactions 
between TJ proteins and resulting alterations in protein com-
plex composition and stability might be a mechanism of bar-
rier regulation.
ZO-1 is thought to primarily regulate paracellular per-
meability  to  uncharged  macromolecules  (Van  Itallie  et  al., 
2009a) via the leak pathway of trans-TJ flux (Anderson and 
Van Itallie, 2009; Turner, 2009; Weber et al., 2010). In con-
trast, conductance across the size- and charge-selective TJ para-
cellular pore pathway appears to be regulated by claudin proteins 
(Simon  et  al.,  1999; Tsukita  and  Furuse,  2000; Van  Itallie   
et al., 2008b; Anderson and Van Itallie, 2009; Rosenthal et al., 
2010). The charge selectivity of these pores is determined by 
specific residues within the first extracellular loop of clau-
dins (Balda et al., 2000; Furuse et al., 2001; Amasheh et al., 
2002; Colegio et al., 2002, 2003; Van Itallie et al., 2003). For 
instance, paracellular pores created by claudin-2 allow small 
cations  and  water  to  pass,  but  exclude  anions  and  larger   
solutes  (Amasheh  et  al.,  2002;  Van  Itallie  et  al.,  2008b;   
A
lthough the C-terminal cytoplasmic tail of the tight 
junction protein occludin is heavily phosphory-
lated,  the  functional  impact  of  most  individual 
sites is undefined. Here, we show that inhibition of CK2-
mediated occludin S408 phosphorylation elevates tran-
sepithelial resistance by reducing paracellular cation 
flux. This regulation requires occludin, claudin-1, claudin-2, 
and ZO-1. S408 dephosphorylation reduces occludin ex-
change, but increases exchange of ZO-1, claudin-1, and 
claudin-2, thereby causing the mobile fractions of these 
proteins to converge. Claudin-4 exchange is not affected. 
ZO-1  domains  that  mediate  interactions  with  occludin 
and claudins are required for increases in claudin-2 ex-
change, suggesting assembly of a phosphorylation-sensitive 
protein complex. Consistent with this, binding of claudin-1 
and claudin-2, but not claudin-4, to S408A occludin 
tail is increased relative to S408D. Finally, CK2 inhibi-
tion  reversed IL-13–induced, claudin-2–dependent bar-
rier loss. Thus, occludin S408 dephosphorylation regulates 
paracellular  permeability  by  remodeling  tight  junction 
protein dynamic behavior and intermolecular interactions 
between occludin, ZO-1, and select claudins, and may 
have  therapeutic  potential  in  inflammation-associated 
barrier dysfunction.
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Results
CK2 decreases epithelial barrier function 
by amplifying paracellular ion flux
To determine if CK2 can regulate epithelial barrier function, 
polarized Caco-2 human intestinal epithelial cells were treated 
with  the  CK2  inhibitors  4,5,6,7-tetrabromobenzotriazole   
(TBB;  IC50  1  µM;  Sarno  et  al.,  2001),  2-dimethylamino-
4,5,6,7-tetrabromo-1H-benzimidazole (DMAT; IC50 0.15 µM; 
Pagano et al., 2004), and tetrabromocinnamic acid (TBCA; IC50 
0.11 µM; Pagano et al., 2007). Each significantly elevated trans-
epithelial electrical resistance (TER) in a dose-dependent man-
ner that correlated with drug potency (Fig. 1 A). Peak TER 
increases were achieved within 3 h and were sustained for at 
least three additional hours of treatment (Fig. 1 B).
Although the prolonged interval over which CK2 inhibi-
tion raises TER could allow protein synthesis or degradation, 
expression of ZO-1, claudin-1, claudin-2, or claudin-4, and the 
TJ-associated MARVEL proteins (TAMPs) occludin, tricellu-
lin, and marvelD3, was unaffected (Fig. S1 A). Expression of 
these proteins was also unaffected by siRNA-mediated CK2 
knockdown (Fig. S1, A–C), which increased TER to an extent 
comparable  to  enzymatic  inhibition.  Moreover,  CK2  knock-
down abrogated the ability of CK2 inhibitors to elevate TER 
(Fig. 1 C). Thus, the observed TER regulation is a function of 
CK2 inhibition, rather than off-target drug effects. Moreover, 
although previous studies have shown that CK2 can stimulate 
Na
+/H
+ exchanger 3 (NHE3; Sarker et al., 2008), which in turn 
can regulate TER (Turner et al., 2000), the effects of CK2 and 
NHE3 inhibition were additive (Fig. S1 D). Thus, the effect of 
CK2 inhibition on barrier function is independent of NHE3.
The 22 ± 1% increase in TER induced by 50 µM TBCA 
was accompanied by a 20 ± 1% decrease in paracellular Na
+ 
flux, but TJ permeability to cations with radii larger than 2.5 Å 
(Fig. 1 D), anions (not depicted), and uncharged macromole-
cules  (Fig.  S1  E)  was  unaffected. Therefore,  CK2  regulates 
paracellular permeability of small cations through the pore 
pathway but does not affect leak pathway flux (Anderson and 
Van Itallie, 2009; Van Itallie et al., 2009b; Yu et al., 2009; Weber 
et al., 2010; Shen et al., 2011).
CK2-mediated barrier regulation is  
occludin dependent
Barrier regulation is commonly associated with TJ protein re-
distribution. Localizations of ZO-1, claudin-1, claudin-2, claudin-4, 
marvelD3, tricellulin, and occludin were therefore evaluated 
before and after CK2 inhibition. Only occludin distribution was 
affected (Fig. 2 A). CK2 inhibition increased TJ-associated   
occludin and decreased the number of occludin-containing   
cytoplasmic vesicles (Fig. 2, B and C). In contrast, CK2, which   
localizes to the cytoplasm, lateral membrane, and TJ of Caco-2 
cells, was not redistributed after enzymatic inhibition (Fig. S1 F). 
Thus, barrier function increases after CK2 inhibition are associ-
ated with occludin redistribution to the TJ. Conversely, occludin 
removal from the TJ promotes barrier loss (Clayburgh et al., 
2005; Shen and Turner, 2005; Murakami et al., 2009; Marchiando 
et al., 2010; Van Itallie et al., 2010). This suggests that TER   
Yu et al., 2009; Muto et al., 2010; Rosenthal et al., 2010). 
These pores appear to primarily be regulated by claudin-2 pro-
tein expression and half-life (Van Itallie et al., 2004; Heller   
et al., 2005; Weber et al., 2010) and, perhaps, by competition 
with other claudin family members (Van Itallie et al., 2001; 
Angelow et al., 2007). Although mathematical models of TJ 
barrier properties suggest that intra-TJ pores have defined open 
probabilities (Claude and Goodenough, 1973; Claude, 1978), 
neither the value nor regulation of this biophysical parameter 
has been determined.
The role of occludin in paracellular barrier function re-
mains controversial (Saitou et al., 2000; Schulzke et al., 2005; 
Yu et al., 2005; Marchiando et al., 2010; Van Itallie et al., 
2010), but hyperphosphorylation of the C-terminal cytoplas-
mic tail is associated with localization at TJs (Sakakibara et al., 
1997; Wong, 1997). Several studies have assessed specific 
phosphorylated residues within occludin, and the region proxi-
mal to the C-terminal coiled-coil occludin/ELL (OCEL) domain 
appears to be a hotspot for functionally relevant sites. For 
example, T403 and T404 phosphorylation enhance both oc-
cludin trafficking to the TJ and paracellular barrier function 
(Suzuki et al., 2009). In contrast, phosphorylation of Y398 
and Y402 reduces occludin–ZO-1 interactions, interferes with 
occludin localization at the TJ, and sensitizes monolayers to 
oxidant-induced barrier disruption (Elias et al., 2009). Similarly, 
phosphorylation of the more distal S490, which is located 
within the OCEL domain, attenuates the interaction between 
occludin and ZO-1 (Sundstrom et al., 2009) and is associated 
with occludin endocytosis and barrier loss (Murakami et al., 
2009).  Thus,  although  hyperphosphorylation  is  associated 
with occludin trafficking to the TJ, the impact of phosphory-
lation at specific sites within the C-terminal cytoplasmic tail 
is highly variable and may, at least in part, reflect modulation 
of ZO-1 binding.
The kinase CK2 (Litchfield et al., 2001; Meggio and 
Pinna,  2003)  is  known  to  phosphorylate  occludin  S408,   
T404,  and,  to  a  lesser  extent,  T400  in  vitro  and  in  vivo   
(Cordenonsi et al., 1999; Smales et al., 2003; Dörfel et al., 
2009). Although the functional significance of CK2-mediated   
occludin  phosphorylation  has  not  been  explored,  S408   
phosphorylation facilitates subsequent CK2-mediated phos-
phorylation  at  T404  and  T400.  This  suggests  that  S408 
phosphorylation is the rate-limiting step in CK2-mediated 
occludin phosphorylation (Dörfel et al., 2009). We therefore 
sought  to  determine  the  molecular  and  functional  conse-
quences of S408 occludin phosphorylation. The data indi-
cate that S408 dephosphorylation reduces paracellular cation 
flux  by  stabilizing  occludin–ZO-1  interactions  that,  in  a   
ZO-1–dependent manner, enhance claudin-1 and claudin-2, but 
not claudin-4, exchange and prevent pore assembly or open-
ing. Conversely, S408 phosphorylation enhances homotypic 
occludin–occludin interactions, releases ZO-1, and promotes 
paracellular cation flux via claudin-1– and claudin-2–based 
pores. We conclude that occludin S408 is a molecular switch 
by which CK2, and, potentially other occludin kinases, regu-
late TJ molecular remodeling, protein interactions, and para-
cellular pore function.567 Occludin S408 regulates epithelial barrier function • Raleigh et al.
The occludin mobile fraction was reduced from 71 ± 4% to   
50 ± 4% (P < 0.01) after CK2 inhibition (Fig. 3, A and B). 
In contrast, mobile fractions of tricellulin or either marvelD3   
splice variant were unaffected (Fig. 3, A and B). CK2 knock-
down both reduced the occludin mobile fraction and rendered 
occludin recovery resistant to pharmacological CK2 inhibition 
(Fig. 3 C; Fig. S2 A; Table I). Thus, CK2 inhibition increases 
both the quantity and stability of TJ-associated occludin while 
increasing barrier function. Together, these data suggest that   
occludin recruitment and stabilization may be involved in the 
observed barrier regulation.
CK2 inhibition stabilizes occludin at  
the TJ in vivo
To determine if the effect of CK2 inhibition on occludin dy-
namic behavior in cell culture is an accurate recapitulation of   
in vivo biology, FRAP was performed using transgenic mice 
expressing EGFP-occludin under control of the villin promoter 
regulation by CK2 may require occludin. To assess this, Caco-2 
cells in which occludin expression was stably knocked down 
were developed. Occludin knockdown monolayers did not in-
crease TER regulation after CK2 inhibition (Fig. 2 D), indicat-
ing an essential role of occludin in this form of barrier regulation. 
However, NHE3 inhibition increased TER of monolayers lack-
ing occludin (Fig. S1 G), demonstrating that occludin knockdown 
monolayers are capable of barrier regulation and providing further 
evidence that the observed effects of CK2 inhibition are not re-
lated to NHE3. Thus, CK2 regulates TJ barrier function in an 
occludin-dependent manner.
CK2 inhibition stabilizes occludin, but not 
other TAMPs, at the TJ
To determine if CK2-dependent barrier regulation is associated 
with alterations in TJ protein dynamic behavior, FRAP was used 
to assess exchange of occludin and the related TAMPs tricellulin, 
marvelD3 variant 1, and marvelD3 variant 2 (Raleigh et al., 2010). 
Figure 1.  CK2 decreases epithelial barrier function by amplifying paracellular ion flux. (A) CK2 inhibitors elevated Caco-2 TER in a dose-dependent man-
ner after 5 h of treatment. (B) CK2 inhibition caused maximal TER increases within 3 h. (C) Chemical inhibition or CK2 knockdown resulted in comparable 
TER increases after 6 h of DMAT (50 µM) treatment. (D) Biionic potentials of sodium, methylamine, ethylamine, tetramethylammonium, tetraethylammonium, 
and N-methyl-d-glucamine were measured 4 h after TBCA (50 µM) addition.JCB • VOLUME 193 • NUMBER 3 • 2011   568
(68 ± 4%, 68 ± 8%, 69 ± 3%, and 70 ± 4%, respectively; Fig. 4,   
A and B). In contrast, the mobile fractions of EGFP-occludin 
T404A/S408A and S408A were significantly reduced (52 ± 3% 
and 49 ± 3%, respectively), and were similar to those of wild-
type and T404A EGFP-occludin after CK2 inhibition (47 ± 2% 
and 45 ± 4%, respectively). Moreover, FRAP behavior of occludin 
T404D/S408D,  T404A/S408A,  S408A,  and  S408D  mutants 
was unaffected by CK2 inhibition (Fig. 4, A and B; Table I). Thus, 
S408, but not T404, is critical to occludin exchange at the TJ. 
S408 is also the key regulator of occludin trafficking, as EGFP-
occludin S408A was enriched at the TJ relative to wild-type or 
S408D EGFP-occludin and neither S408A nor S408D mutants 
were redistributed after CK2 inhibition (Fig. S3, A and B).
Occludin phosphorylation at  
S408 is required for CK2-mediated  
barrier regulation
The effect of S408 mutations on FRAP behavior and TJ local-
ization suggests that this residue may also be essential for 
CK2-mediated barrier regulation. To test this hypothesis, we 
measured the effect of CK2 inhibition on TER of wild-type or 
occludin knockdown Caco-2 monolayers as well as on TER of 
knockdown  cell  lines  stably  expressing  wild-type  or  mutant 
EGFP-occludin. Neither occludin knockdown nor expression of 
(Marchiando et al., 2010). CK2 inhibition significantly de-
creased the mobile fraction of occludin, from 57 ± 2% to 39 ± 1%, 
in vivo (P < 0.01) without altering the t1/2 of recovery or TJ pro-
tein expression (Fig. 3 D; Fig. S2, B–D). Thus, CK2 inhibition sta-
bilizes occludin at the TJ in vivo in a manner similar to that 
observed in vitro. Notably, the failure of CK2 inhibition to 
affect paracellular flux of water or BSA in vivo (Fig. S2 E) is 
consistent with the in vitro data showing that CK2 affects 
size-selective barrier regulation and that NHE3 is not involved 
in this process.
Phosphorylation at S408 is required for 
CK2-mediated occludin regulation
To identify the residue(s) responsible for CK2 regulation of bar-
rier function and occludin exchange, alanine (A) or aspartic 
acid (D) mutations were introduced at T404 and S408, the two 
primary sites of CK2-mediated occludin phosphorylation. EGFP-
occludin mutants were expressed in occludin knockdown Caco-2 
cells to avoid potential interactions with endogenous wild-type 
occludin and were efficiently trafficked to TJs. Similar to en-
dogenous occludin, wild-type EGFP-occludin was enriched at 
the TJ after CK2 inhibition (Fig. S3, A and B). The mobile frac-
tions of T404D/S408D, T404A, and S408D mutants were indis-
tinguishable from that of wild-type EGFP-occludin at baseline 
Figure 2.  CK2-mediated barrier regulation is occludin dependent. (A) Effect of CK2 inhibition (50 µM DMAT) on distribution of transmembrane TJ proteins 
(green) and ZO-1 (red). Bar, 10 µm. (B) Quantitative analysis of occludin enrichment at the TJ. (C) Quantitative analysis of number of occludin-containing 
vesicles. (D) CK2 inhibition (50 µM DMAT) failed to elevate TER of occludin knockdown monolayers.569 Occludin S408 regulates epithelial barrier function • Raleigh et al.
as recombinant proteins and immobilized on glutathione-agarose. 
These were used to probe Caco-2 lysates, and captured proteins 
were analyzed by immunoblot. Consistent with a role for S408 
in regulation of occludin dimerization, the S408D occludin tail 
captured 2.4 ± 0.05-fold more endogenous occludin than the 
S408A tail (Fig. 5 A; P < 0.05). In contrast, the S408A tail re-
covered claudin-1 and claudin-2 more efficiently, and captured 
5.1 ± 1.3 (P < 0.01) and 2.8 ± 0.3-fold (P < 0.01) more of each, 
respectively, relative to the S408D tail. These differences were 
specific to claudin-1 and claudin-2, as similar amounts of mar-
velD3 and claudin-4 were captured by the three occludin tail 
constructs, and GST alone failed to recover any of these pro-
teins (Fig. 5 A).
The occludin cytoplasmic tail has not been reported to   
interact directly with claudins. However, ZO-1 interacts with both 
occludin and claudins (Furuse et al., 1994; Itoh et al., 1999a; 
Nusrat et al., 2000; Schmidt et al., 2001). Thus, ZO-1 may serve 
as an intermediate in occludin–claudin-1/claudin-2 interactions 
that are regulated by S408 phosphorylation. To assess direct   
interactions between ZO-1 and occludin, binding of recombinant 
VSV G epitope-tagged ZO-1 U5-GuK domain (Kreis, 1986; 
Raleigh et al., 2010) to immobilized GST-occludin 383–522 
S408D and S408A was assessed. Both GST-occludin tails, but 
EGFP-occludin constructs altered expression of endogenous TJ 
proteins or CK2 (Fig. S3 C). However, occludin knockdown   
did reduce steady-state TER (Fig. S3 D). Expression of EGFP-
tagged wild-type and T404A occludin, but not EGFP alone, re-
stored TER responses to CK2 inhibition (Fig. 4 C). In contrast, 
neither T404D/S408D nor S408A EGFP-occludin–expressing 
monolayers were sensitive to CK2 inhibition. Therefore, both 
occludin expression and phosphorylation at S408 are necessary 
for CK2-mediated barrier regulation. Moreover, the parallel 
roles of S408 in occludin trafficking and exchange as well as 
barrier regulation suggests that these processes are linked.
Occludin S408 dephosphorylation 
enhances interactions with claudin-1, 
claudin-2, and ZO-1
S408 is located within a structurally disordered region of the 
cytoplasmic C-terminal tail of human occludin (Li et al., 2005; 
Walter et al., 2009). This site is adjacent to C409, which is criti-
cal for occludin dimerization (Li et al., 2005; Walter et al., 2009), 
and suggests that that S408 phosphorylation may modify occlu-
din association with other proteins. To explore this hypothesis, 
GST-fusion constructs of wild-type occludin 383–522 or mutants 
with  either  S408D  or  S408A  substitutions  were  expressed   
Figure 3.  CK2 inhibition stabilizes occludin at the TJ in vitro and in vivo. (A) Kymographs of EGFP-TAMP FRAP, with or with out DMAT treatment (50 µM) 
at bicellular TJ regions. Bar, 3 µm. (B) Effect of CK2 inhibition (50 µM DMAT) on EGFP-TAMP mobile fractions. (C) EGFP-occludin mobile fraction after CK2 
knockdown or chemical CK2 inhibition (50 µM DMAT). (D) Effect of CK2 inhibition (50 µM DMAT) on EGFP-occludin FRAP in mouse jejunum in vivo.JCB • VOLUME 193 • NUMBER 3 • 2011   570
Table I.  The dynamic behavior of TJ components involved in CK2-mediated epithelial barrier regulation
Epithelium Pharmacological  
CK2 inhibition
Mobile fraction  
(%)
Occludin Wild type 68 ± 3
†
Wild type √ 52 ± 5
a
CK2 knockdown  53 ± 2
a
CK2 knockdown  √ 48 ± 2
a
ZO-1 knockdown  67 ± 8
In vivo 57 ± 2
†
In vivo √ 39 ± 1
a
T404D/S408D Occludin knockdown  68 ± 4
Occludin knockdown  √ 69 ± 6
T404A/S408A Occludin knockdown  52 ± 3
a
Occludin knockdown  √ 50 ± 3
a
T404A Occludin knockdown  68 ± 8
Occludin knockdown  √ 45 ± 4
a
S408A Occludin knockdown  49 ± 3
a
Occludin knockdown  √ 48 ± 7
a
ZO-1 knockdown  70 ± 1
S408D Occludin knockdown  69 ± 3
Occludin knockdown  √ 72 ± 3
ZO-1 knockdown 66 ± 9
Claudin-1 Occludin knockdown  36 ± 2
Occludin knockdown/wild-type occludin expression 37 ± 1
†
Occludin knockdown/S408D occludin expression 35 ± 4
Occludin knockdown/S408A occludin expression 57 ± 3
a
Claudin-2 Wild type  33 ± 3
†
Occludin knockdown  33 ± 3
Occludin knockdown/wild-type occludin expression 31 ± 5
Occludin knockdown/S408D occludin expression 25 ± 6
Occludin knockdown/S408A occludin expression 51 ± 2
a
Wild type √ 51 ± 5
Occludin knockdown  √ 27 ± 1
ZO-1 knockdown  √ 32 ± 2
ZO-1 knockdown/ZO-1 expression 35 ± 6
ZO-1 knockdown/ZO-1 expression √ 54 ± 4
a
ZO-1 knockdown/ZO-1 PDZ1 expression 35 ± 4
ZO-1 knockdown/ZO-1 PDZ1 expression √ 28 ± 4
ZO-1 knockdown/ZO-1 U5-Guk expression 33 ± 5
ZO-1 knockdown/ZO-1 U5-Guk expression √ 32 ± 3
ZO-1 Wild type 48 ± 3
†
Wild type √ 60 ± 4
a
Occludin knockdown  46 ± 4
Occludin knockdown  √ 45 ± 4
Occludin knockdown/wild-type occludin expression 45 ± 4
Occludin knockdown/S408D occludin expression 43 ± 4
Occludin knockdown/S408A occludin expression 61 ± 4
a
Wild-type/large area FRAP (center) 51 ± 4
Wild-type/large area FRAP (edge) 50 ± 5
†
Wild-type/large area FRAP (center) √ 46 ± 1
Wild-type/large area FRAP (edge) √ 58 ± 4
a
aData are significant (P < 0.05) relative to control conditions (†).
not GST alone, bound to ZO-1 U5-GuK (Fig. 5 B). However, 
binding to the S408A tail was 3.2 ± 0.3-fold greater than to the 
S408D mutant (P < 0.01). These results suggest that interactions 
between occludin and ZO-1 are weakened by S408 phosphory-
lation. Together with the enhanced capture of full-length, endog-
enous occludin by the S408D occludin tail, these data also 571 Occludin S408 regulates epithelial barrier function • Raleigh et al.
Occludin S408 dephosphorylation 
increases claudin-1, claudin-2, and ZO-1 
exchange at the TJ
The studies above used cell lysates and recombinant proteins to 
show that S408 phosphorylation reduces interactions between 
occludin, ZO-1, claudin-1, and claudin-2. However, the large 
number of protein interactions at TJs may allow larger com-
plexes to form within intact epithelial monolayers and make 
S408 phosphorylation irrelevant. Thus, as an indirect measure 
of protein interactions, mobile fractions were assessed by FRAP 
in confluent Caco-2 monolayers. Pharmacological CK2 inhibi-
tion in wild-type monolayers increased the mobile fraction of 
TJ-associated mRFP1-ZO-1 from 48 ± 3% to 60 ± 4% (Fig. 5 D; 
P < 0.05) but did not affect ZO-1 exchange in occludin knock-
down monolayers. Moreover, S408A, but not wild-type or 
S408D EGFP-occludin increased mRFP1-ZO-1 exchange in a 
support the hypothesis that S408 phosphorylation acts as a mo-
lecular switch that determines whether occludin forms homo-
dimers or heterotypic interactions with ZO-1.
The enhanced association of the ZO-1 U5-GuK construct 
with S408A occludin tail is consistent with a model where   
ZO-1 mediates interactions between occludin and claudin-1 
or claudin-2. To determine if ZO-1 is required for claudin cap-
ture by immobilized GST-occludin 383–522, lysates of ZO-1 
knockdown Caco-2 cells were probed with immobilized S408A 
and  S408D  occludin  tails.  ZO-1  knockdown  almost  com-
pletely eliminated claudin-2 recovery, and there was no dif-
ference  between  amounts  captured  by  S408A  and  S408D 
occludin tails (Fig. 5 C). Thus, ZO-1 mediates S408 phos-
phorylation-regulated occludin interactions with claudin-2. 
Importantly, ZO-1 knockdown did not affect expression of ZO-2, 
or claudins 1, 2, or 4 (Fig. S4 A).
Figure 4.  S408 phosphorylation is required for CK2-mediated regulation of occludin dynamics and barrier function. (A and B) FRAP analysis of EGFP-
occludin mutants expressed in occludin knockdown Caco-2 cells. Bar, 3 µm. (C) Expression of EGFP or EGFP-occludin mutants in occludin knockdown 
(KD) Caco-2.JCB • VOLUME 193 • NUMBER 3 • 2011   572
claudin-2 (Fig. 5 E); CK2 inhibition had a similar effect on 
mRFP1–claudin-2 exchange (Fig. 5 F). In contrast, FRAP behavior 
of mRFP1–claudin-4 was comparable in occludin knockdown 
monolayers and those expressing wild-type, S408D, or S408A 
EGFP-occludin (Fig. 5 E). Thus, in a manner that parallels the pro-
tein binding assay data, occludin S408 dephosphorylation affects 
exchange of claudin-1 and claudin-2, but not claudin-4.
manner similar to CK2 inhibition (Fig. 5 D; P < 0.05). Thus, 
occludin S408 dephosphorylation enhances ZO-1 exchange at 
the TJ.
Based on the in vitro binding studies, the effects of wild-type, 
S408D, and S408A EGFP-occludin expression on mRFP1-claudin 
exchange were assessed. S408A EGFP-occludin expression mark-
edly increased the mobile fractions of both mRFP1–claudin-1 and 
Figure 5.  Occludin S408 dephosphorylation enhances interactions with claudin-1, claudin-2, and ZO-1, and their exchange at the TJ. (A) GST-occludin 
C-terminal tails (383–522) immobilized on glutathione-agarose were used to probe Caco-2 lysates, and recovered proteins assessed by SDS-PAGE   
immunoblot. (B) GST-occludin C-terminal tails were used to capture VSV G-ZO-1-U5-GuK. (C) GST-occludin C-terminal tails were used to probe control and 
ZO-1 knockdown Caco-2 lysates, as above. (D) FRAP of mRFP1-ZO-1 was assessed in control and occludin knockdown monolayers as well as occludin 
knockdown monolayers expressing wild-type, S408D, or S408A EGFP-occludin. (E) FRAP of mRFP1-tagged claudin-1, claudin-2, and claudin-4 were as-
sessed in occludin knockdown monolayers either alone or with wild-type, S408D, or S408A EGFP-occludin. (F) FRAP analysis of mRFP1-claudin-2 expressed 
in wild-type, occludin knockdown, or ZO-1 knockdown monolayers as well as ZO-1 knockdown monolayers expressing wild-type, PDZ1, or U5-GuK 
EGFP-ZO-1. (G) FRAP of wild-type, S408D, and S408A EGFP-occludin in ZO-1 knockdown monolayers. (H) EGFP-ZO-1 fluorescent recovery at the center 
(circles) and edges (squares) of elongated bleach regions. Bar, 6 µm. Chemical CK2 inhibition throughout this figure was with 50 µM TBCA573 Occludin S408 regulates epithelial barrier function • Raleigh et al.
intramembrane diffusion. Although multiple approaches can be 
used, intramembrane diffusion and cytosolic exchange are most 
readily distinguished by analysis of FRAP over extended TJ re-
gions (Shen et al., 2008). As reported previously in MDCK cells 
(Shen et al., 2008), EGFP–ZO-1 recovery in control Caco-2 
cells was uniform over the bleached region, consistent with cyto-
solic exchange (Fig. 5 H). In contrast, EGFP–ZO-1 recovery at 
the periphery of bleached regions was significantly increased 
after CK2 inhibition (Table I; P < 0.05), whereas recovery at the 
center of bleached regions was unchanged (Fig. 5 H). Thus, the 
observed increases in ZO-1 mobile fraction are due to enhanced 
recovery at the edges in a pattern typical of intramembranous diffu-
sion. These data support the hypothesis that S408 dephosphoryla-
tion enhances occludin association with ZO-1 in living cells.
CK2-mediated barrier regulation requires 
ZO-1, claudin-1, and claudin-2
Together with reports that claudin-2 creates a small cation- 
selective paracellular pore (Amasheh et al., 2002; Van Itallie et al., 
2008b; Yu et al., 2009), the increased claudin-2 mobile fraction 
and decreased paracellular cation permeability induced by CK2 
inhibition suggest that the S408 dephosphorylation may disrupt 
assembly or opening of claudin-2 pores. This would directly 
link occludin dynamic behavior to TJ barrier function and sug-
gest that the effects of CK2 inhibition on cation-selective paracel-
lular flux may require occludin, ZO-1, and claudin-2. Consistent 
with this, CK2 inhibition induced dose-dependent TER increases 
and Na
+ selectivity decreases in control, but not occludin knock-
down, monolayers (Fig. 6, A and B). Thus, although occludin is 
not thought to form paracellular pores, it is required for regula-
tion of paracellular Na
+ conductance and barrier function after 
CK2 inhibition. Similarly, ZO-1 knockdown eliminated TER 
and Na
+ selectivity responses to CK2 inhibition (Fig. 6, C and D). 
Thus, consistent with the in vitro binding and FRAP data, ZO-1 
is also required for CK2-mediated regulation of paracellular 
cation pores.
Both biochemical and FRAP data suggest that roles of   
occludin and ZO-1 in CK2-mediated barrier regulation are, pri-
marily, to control claudin-2 function. This is also consistent with 
the observation that CK2 inhibition regulates paracellular flux 
of small cations that are characteristic of claudin-2–based pores. 
To directly assess the participation of claudin-2 in CK2-mediated 
barrier regulation, stable claudin-2 knockdown Caco-2 cells 
were developed (Fig. S4 B). As expected, claudin-2 knockdown 
markedly increased TER (Fig. 6 E), reduced Na
+ selectivity 
To determine whether the observed increase in claudin-2 
exchange requires occludin or ZO-1, mRFP1–claudin-2 FRAP 
was assessed in wild-type, occludin knockdown, and ZO-1 
knockdown monolayers. Although pharmacological CK2 inhibi-
tion increased mRFP1–claudin-2 exchange in wild-type mono-
layers, the mRFP1–claudin-2 mobile fraction was unchanged in 
occludin or ZO-1 knockdown monolayers (Fig. 5 F). Thus, sim-
ilar to the binding assays, the FRAP studies indicate that ZO-1 
is required for the effects of occludin S408 dephosphorylation 
on claudin-2 exchange.
The data support the hypothesis that ZO-1 acts as a scaf-
fold that links occludin to claudin-2. The sites within ZO-1 that 
mediate binding to claudins (PDZ1) and occludin (U5-GuK)   
are well defined (Fanning et al., 1998, 2007; Itoh et al., 1999a; 
Schmidt et al., 2004; Li et al., 2005; Müller et al., 2005; Umeda 
et al., 2006). To assess the roles of these ZO-1 domains in regu-
lation of claudin-2 exchange, ZO-1 knockdown Caco-2 cells were 
cotransfected with mRFP1–claudin-2 and either wild-type, 
PDZ1, or U5-GuK EGFP-ZO-1. Wild-type EGFP–ZO-1 re-
stored sensitivity of mRFP1–claudin-2 recovery to CK2 inhibi-
tion. In contrast, EGFP–ZO-1 lacking either the PDZ1 or U5-GuK 
domain failed to restore sensitivity of mRFP1–claudin-2 recov-
ery to CK2 inhibition (Fig. 5 F).
When taken together with the in vitro binding assays, the 
FRAP studies of confluent monolayers suggest that physical inter-
actions among occludin, ZO-1, and select claudins are facilitated 
by occludin S408 dephosphorylation. Consistent with this, the 
markedly different occludin, ZO-1, and claudin-2 mobile frac-
tions of 68 ± 3%, 48 ± 3%, and 33 ± 3%, respectively, converge to 
52 ± 5%, 60 ± 4%, and 51 ± 5%, respectively, after CK2 inhibition 
(Table II). Moreover, (a) the mobile fraction of wild-type occludin 
after CK2 inhibition is similar to that of EGFP-occludin S408A; 
(b) FRAP behaviors of wild-type, S408D, and S408A EGFP- 
occludin are similar in ZO-1 knockdown cells (Fig. 5 G);   
and (c) S408A occludin expression increases ZO-1, claudin-1,   
and claudin-2 exchange in a manner similar to CK2 inhibition 
(Table II). These data are all consistent with the hypothesis that 
occludin S408 dephosphorylation promotes assembly of protein 
complexes that include occludin, ZO-1, claudin-1, and claudin-2.
Previous analyses have shown that fluorescent recovery of 
occludin and ZO-1 occur by diffusion within the plasma mem-
brane and exchange with cytosolic pools, respectively (Shen   
et al., 2008). Thus, if occludin S408 dephosphorylation does 
promote complex assembly, the mechanism of ZO-1 recovery 
would be expected to change to include a component due to   
Table II.  CK2-mediated regulation of occludin, claudin-1, claudin-2, and ZO-1 mobile fractions
Condition Occludin Claudin-1 Claudin-2 ZO-1
Steady state 68 ± 3 36 ± 2 33 ± 3 48 ± 3
CK2 inhibition 52 ± 5
a,b 51 ± 5
a 60 ± 4
a
Occludin knockdown/occludin S408A 49 ± 3
a 57 ± 3
a 51 ± 2
a 61 ± 4
a
Occludin knockdown/CK2 inhibition 27 ± 1 45 ± 4
ZO-1 knockdown/CK2 inhibition 32 ± 2
aData changes are significant (P < 0.05) relative to steady state.
bData were confirmed by in vitro CK2 knockdown and in vivo CK2 inhibition.JCB • VOLUME 193 • NUMBER 3 • 2011   574
disruption of barrier regulatory mechanisms, as claudin-2 knock-
down monolayers remained sensitive to myosin light chain   
kinase inhibition (Fig. S4 D). Therefore, in a manner that paral-
lels FRAP and in vitro binding data, claudin-2 is required for 
CK2-mediated regulation of paracellular cation permeability.
(Fig.  6  E),  and  reduced  paracellular  permeability  to  cations 
smaller than 2.5 Å (Fig. S4 C). In addition, claudin-2 knock-
down monolayers displayed only limited TER increases (Fig. 6 F) 
and no change in Na
+ selectivity (Fig. 6 G) after CK2 inhibition. 
The small size of the TER increases was not due to global 
Figure 6.  CK2-mediated barrier regulation requires ZO-1 and claudin-2. (A and B) TER and PNa
+/PCl
 responses of control and occludin knockdown 
monolayers to CK2 inhibition. (C and D) TER and PNa
+/PCl
 responses of control and ZO-1 knockdown monolayers to CK2 inhibition. (E) TER and PNa
+/
PCl
 after claudin-1 and claudin-2 knockdown. (F and G) TER and PNa
+/PCl
 responses of control and claudin-2 knockdown monolayers to CK2 inhibition. 
(H and I) TER and PNa
+/PCl
 responses of control, claudin-1, claudin-2, and double-knockdown monolayers to CK2 inhibition. (J) Tight junction protein 
expression in Caco-2 and T84 monolayers, before or after 12 h of IL-13 treatment (1 ng/ml). (K and L) Effect of CK2 inhibition (50 µM TBCA) on TER and 
PNa
+/PCl
 of control and IL-13–treated T84 monolayers.575 Occludin S408 regulates epithelial barrier function • Raleigh et al.
IL-13–induced barrier dysfunction and CK2 may be an attrac-
tive target for future pharmacological modulation of pathophys-
iological barrier defects.
Discussion
Despite a multitude of described interactions between TJ pro-
teins, little information is available for understanding the means 
by which separate TJ components work together to regulate bar-
rier function. Thus, identification of the molecular mechanisms 
that underlie TJ regulation is a major challenge that must be   
addressed during the next phase of TJ discovery. To begin to 
explore these processes, we assessed the effect of occludin 
phosphorylation on TJ molecular structure and barrier function. 
We focused on CK2, which acts as an occludin kinase in vivo 
and in vitro (Cordenonsi et al., 1997, 1999; Smales et al., 2003; 
Dörfel et al., 2009), but has not been associated with TJ regula-
tion.  The  data  show  that  CK2-mediated  phosphorylation  of   
occludin S408 modulates interactions between occludin, ZO-1, 
claudin-1, and claudin-2, and implicate S408 phosphorylation 
as a molecular switch that regulates TJ structure and paracellu-
lar pore pathway flux.
A model of CK2-mediated, occludin  
S408 phosphorylation-dependent  
barrier regulation
The data presented here show that CK2 inhibition reduces para-
cellular cation flux. This regulation requires occludin, and can 
be reproduced by S408A occludin expression without CK2 in-
hibition. ZO-1, claudin-1, and claudin-2 are also required for 
barrier regulation after CK2 inhibition, suggesting that occludin 
S408 dephosphorylation regulates claudin pore function via 
ZO-1 (Fig. 7). Thus, although we have focused on CK2, the 
phosphatase responsible for S408 dephosphorylation may also 
be important.
We used a combination of morphological and biochemical 
approaches to determine the mechanisms by which TJ proteins 
contribute to CK2-mediated barrier regulation. Morphometric 
analyses showed increased TJ localization of occludin after 
CK2 inhibition or S408A mutation. In binding assays, S408A 
occludin tail recovered more claudin-1 and claudin-2, but not 
claudin-4, from cell lysates, and also demonstrated enhanced 
ZO-1 binding, relative to a S408D mutant. Consistent with a role 
for ZO-1 as a scaffold, claudin-2 recovery from ZO-1 knock-
down cell lysates was poor and similar for both occludin tails. 
Thus, static analyses of subcellular localization and in vitro 
binding suggest that S408 dephosphorylation promotes occlu-
din trafficking to the TJ and physical association with ZO-1, 
claudin-1, and claudin-2.
Although a great deal has been learned from in vitro 
binding studies (Furuse et al., 1994; Itoh et al., 1997, 1999b; 
Fanning et al., 1998, 2002; Cordenonsi et al., 1999; Wittchen   
et al., 1999; Barritt et al., 2000; D’Atri and Citi, 2001; Meyer   
et al., 2002; Kale et al., 2003; Betanzos et al., 2004; Li et al., 
2005; Müller et al., 2005; Seth et al., 2007; Van Itallie et al., 
2008a), they do not provide information about dynamic inter-
actions, are not generally used to measure protein interaction   
The  effect  of  CK2  inhibition  on TER  was  markedly   
reduced by claudin-2 knockdown. Nevertheless, a slight, al-
though statistically significant, increase in TER was induced   
by 50 µM TBCA (Fig. 6 F). This could reflect off-target effects 
of TBCA at higher doses, such as GSK3 inhibition (Pagano   
et al., 2007). However, the observations that occludin or ZO-1 
knockdown completely blocked the effects of TBCA, even at 
50 µM (Fig. 6, A–D), argue against this explanation. Given that 
claudin-1 recovery and FRAP behavior are also modulated by 
S408 dephosphorylation, it was reasonable to hypothesize that 
claudin-1 could be responsible for the residual effects of 50 µM 
TBCA on TER of claudin-2 knockdown monolayers. Transient 
claudin-1 knockdown (Fig. S4 E) increased baseline TER, but 
to a much smaller degree than claudin-2 knockdown (Fig. 6 E), 
suggesting that claudin-1 enhances paracellular permeability. 
However, claudin-1 knockdown in cells lacking claudin-2 reduced 
TER, relative to claudin-2 knockdown alone, suggesting that   
claudin-1 may enhance barrier function in some contexts. Thus, 
claudin-1 may have both pore-forming and barrier-sealing func-
tions. Although further study is required, this interpretation could 
be consistent with diverse but poorly defined claudin-1 functions 
in enhancing barrier function of MDCK monolayers, endothelial 
monolayers, and mouse skin (Inai et al., 1999; Furuse et al., 2002; 
Fujibe et al., 2004), as well as preventing congenital liver and skin 
disease in human patients (Hadj-Rabia et al., 2004).
Much like claudin-2 knockdown, claudin-1 knockdown re-
duced, but did not eliminate TER increases after CK2 inhibition 
(Fig. 6 H). However, combined claudin-1 and claudin-2 knock-
down completely prevented TER increases induced by CK2 inhi-
bition (Fig. 6 H). In contrast, claudin-1 knockdown did not 
prevent CK2 inhibitor-induced PNa
+/PCl
 decreases, and charge 
selectivity responses of claudin-1/claudin-2 double knockdown 
monolayers were indistinguishable from those with only claudin-2 
knockdown (Fig. 6 I). These data suggest that although claudin-1 
contributes to CK2-mediated TER regulation, it participates by a 
mechanism that is distinct from claudin-2–dependent modula-
tion of paracellular Na
+ pathway permeability.
CK2 inhibition corrects pathophysiologic 
barrier dysfunction
Claudin-2 expression is markedly up-regulated in inflammatory 
bowel disease (Heller et al., 2005; Prasad et al., 2005; Holmes 
et al., 2006), likely as a result of IL-13 signaling (Heller et al., 
2005; Prasad et al., 2005; Fichtner-Feigl et al., 2006, 2008). 
This can be reproduced in vitro (Heller et al., 2005; Weber et al., 
2010), but the effect is limited in Caco-2 monolayers, which ex-
press claudin-2 constitutively. In contrast, T84 intestinal epithe-
lial cells normally possess little claudin-2, but IL-13 markedly 
up-regulates claudin-2 expression to reduce TER and increase 
PNa
+/PCl
 (Prasad et al., 2005; Weber et al., 2010). To deter-
mine  if  CK2  inhibition  could  correct  IL-13–induced  barrier 
dysfunction, T84 cells were treated with IL-13 to induce a 3.0 ± 
0.2-fold increase in claudin-2 expression (Fig. 6 J), 23 ± 2% re-
duction in TER (Fig. 6 K), and 58 ± 11% increase in PNa
+/PCl
 
(Fig. 6 L). Remarkably, subsequent CK2 inhibition completely 
reversed IL-13–induced TER loss (Fig. 6 K) and PNa
+/PCl
  
increase (Fig. 6 L). Thus, CK2 inhibition can acutely reverse   JCB • VOLUME 193 • NUMBER 3 • 2011   576
with increased occludin localization at the TJ under these con-
ditions. Although in vitro binding data show that occludin 
S408A mutation enhances occludin tail binding to ZO-1 and, 
via ZO-1, to claudin-1 and claudin-2, CK2 inhibition or S408A 
mutation increased mobile fractions of ZO-1 and these clau-
dins. These data could be seen as contradictory, as one might 
presume that increased protein interactions should reduce the 
mobile fraction. However, this assumes that FRAP occurs entirely 
affinities, and cannot account for changes in protein structure or 
other regulatory events within live cells. We have therefore used 
mobile fraction as a measure of protein interactions in living 
cells. Although this is an indirect approach that has its own 
shortcomings, the combination of FRAP with in vitro binding 
data can be a powerful tool in analysis of protein interactions 
and function. Our studies show that both CK2 inhibition and 
S408A mutation reduce occludin mobile fraction, consistent 
Figure 7.  Model of CK2-mediated regulation of TJ structure, dynamic behavior, and barrier function through occludin S408 phosphorylation. Proposed 
organization, interactions, and dynamic behavior of proteins involved in TJ regulation by CK2. (A) CK2-mediated phosphorylation of S408 enhances 
occludin self-association, increases the occludin mobile fraction, and reduces occludin association with ZO-1, claudin-1, and claudin-2. This promotes flux 
across claudin-2, and, to a lesser extent, claudin-1 pores, thereby increasing paracellular cation flux. (B) When dephosphorylated at S408, occludin is 
stabilized at the TJ through enhanced association with ZO-1 via the U5-GuK domain. ZO-1 also facilitates indirect interactions between occludin and claudin-2, 
which associates with ZO-1 via the PDZ1 domain, thereby acting as a scaffold to organize a complex. As a result, dynamic behaviors of occludin, ZO-1, 
claudin-1, and claudin-2 converge, and function of claudin-1 and claudin-2 paracellular pores is reduced.577 Occludin S408 regulates epithelial barrier function • Raleigh et al.
(Daugherty et al., 2007; Lim et al., 2008a,b; Piontek et al., 2008; 
Piehl et al., 2010). However, because at least some of the inter-
actions described here must occur within the cytoplasm, intra-
cellular claudin domains (Itoh et al., 1999a; Hamazaki et al., 
2002; Van Itallie et al., 2004, 2005; Tanaka et al., 2005), e.g., 
the N-terminal tail, intracellular loop, or C-terminal tail, should 
also be considered.
Mechanisms by which occludin S408 
serves as a molecular switch
The residues phosphorylated by CK2, including S408, are located 
immediately upstream of the OCEL domain that mediates occlu-
din self-association, ZO-1 binding, and interactions with other 
proteins (Furuse et al., 1994; Fanning et al., 1998; Nusrat et al., 
2000;  Li  et  al.,  2005;  Blasig  et  al.,  2006).  Occludin  residues   
416–522 form three -helices with a positively charged surface 
that binds ZO-1; replacement of these residues with aspartic acid 
abolishes both binding to ZO-1 and occludin trafficking to cell 
contacts (Li et al., 2005). The data reported here and those re-
ported by others suggest that phosphorylation events just proximal 
to the OCEL domain regulate occludin–ZO-1 interactions and oc-
cludin trafficking (Kale et al., 2003; Elias et al., 2009; Murakami 
et al., 2009; Suzuki et al., 2009). Specifically, our studies indicate 
that S408 functions as a molecular switch that determines 
whether  occludin  forms  homodimers  or  heterotypic  inter-
actions with ZO-1 and, therefore, suggest that S408 phosphoryla-
tion regulates coiled-coil domain structure. However, although 
crystal structure of recombinant occludin tails composed of resi-
dues 383–522 or 416–522 has been reported (Li et al., 2005), 
these constructs were not phosphorylated and there is no informa-
tion available to describe the effect of phosphorylation events on 
coiled-coil domain structure. Nevertheless, it is interesting to note 
that both recombinant occludin tails behaved as monomers (Li et 
al., 2005), consistent with our hypothesis that dephosphorylation 
of S408 prevents occludin self-association.
Occludin regulates leak and pore  
pathway function
Both in vitro and in vivo studies suggest that occludin is not re-
quired for TJ assembly or development of barrier function (Saitou 
et al., 2000; Schulzke et al., 2005; Yu et al., 2005). This has led 
some to conclude that occludin is either a regulatory protein or is 
wholly unimportant to TJ function. Consistent with the former 
interpretation, occludin has been implicated in regulation of leak 
pathway flux of large macromolecules by studies of occludin 
knockdown, overexpression, or mutation in MDCK monolayers 
(Balda et al., 1996; Yu et al., 2005). Moreover, recent in vitro and 
in vivo work has demonstrated a critical role for occludin in cyto-
kine-dependent leak pathway regulation (Marchiando et al., 2010; 
Van Itallie et al., 2010). Given that the occludin tail binds directly 
to ZO-1, but not claudins, this also agrees with recent data showing 
that ZO-1 is required for leak pathway regulation (Van Itallie et al., 
2009a). Our observation that occludin phosphorylation modifies 
permeability of claudin-based pores was, therefore, unexpected. 
Thus, these new data add to the functions assigned to occludin and 
show that, beyond regulating the TJ leak pathway, occludin also 
contributes to control of pore pathway permeability.
by diffusion, which is not the case (Shen et al., 2008). Here, the 
in vitro binding and FRAP data can be resolved by a model in 
which occludin dimers form more readily after S408 phosphory-
lation and are more mobile within the TJ, perhaps because they 
are not anchored by ZO-1, whereas binding of occludin and 
ZO-1 after S408 dephosphorylation disrupts interactions that 
anchor ZO-1 and, in turn, some claudins (Fig. 7). This will be 
an important issue to address in the future.
Previous studies have correlated overall occludin hyper-
phosphorylation with TJ localization (Sakakibara et al., 1997; 
Wong, 1997). Although correct at a global level (Seth et al., 
2007), this is not necessarily true of specific phosphorylation 
sites within the C-terminal occludin tail. For example, phos-
phorylation of T403 and T404 facilitates trafficking to the epi-
thelial TJ (Suzuki et al., 2009), whereas phosphorylation of 
Y398 and Y402 interferes with ZO-1 binding and TJ trafficking 
(Elias et al., 2009), and S490 phosphorylation results in ubiqui-
tination, endocytosis, and downstream endothelial barrier loss 
(Murakami et al., 2009; Sundstrom et al., 2009). Thus, phos-
phorylation of specific sites within the occludin C-terminal tail 
may either enhance or diminish occludin TJ localization and 
barrier function. Our results show that S408 phosphorylation 
decreases occludin localization and stability at the TJ and also 
reduces interactions with ZO-1. Conversely, S408 dephosphory-
lation, or mutation to alanine, stabilizes and increases the 
amount of occludin at the TJ, enhances interactions with ZO-1, 
promotes association with claudin-1 and claudin-2, and reduces 
paracellular ion flux. However, ZO-1 is required for occludin sta-
bilization, claudin binding, and barrier regulation after S408 de-
phosphorylation, suggesting that physical interactions between 
occludin and ZO-1 are critical mediators of these events. Interest-
ingly, similar to myosin light chain kinase-dependent control of 
barrier function (Yu et al., 2010) and integrity (Van Itallie et al., 
2009a), but in contrast to TJ assembly (McNeil et al., 2006; Shin 
and Margolis, 2006; Umeda et al., 2006), ZO-2 cannot substitute 
for ZO-1 in occludin S408-mediated TJ regulation.
Although changes in steady-state distributions were not 
detected, FRAP studies revealed increases in ZO-1, claudin-1, 
and  claudin-2  mobile  fractions  after  CK2  inhibition  and 
S408A mutation. This resulted in convergence of occludin, 
ZO-1, claudin-1, and claudin-2 mobile fractions after occlu-
din S408 dephosphorylation, and, for claudin-2, required that 
ZO-1 contain both PDZ1 and U5-GuK domains. Further, in 
vitro binding studies showed enhanced association of ZO-1, 
claudin-1, and claudin-2 with S408A, relative to S408D, oc-
cludin tail. As a whole, these data strongly support the idea 
that S408 dephosphorylation facilitates assembly of a protein 
complex to regulate molecular structure and barrier proper-
ties of the TJ.
In contrast to claudin-1 and claudin-2, neither in vitro 
binding nor FRAP analyses detected any changes in claudin-4 
after S408 dephosphorylation. Thus, in addition to differences 
within the first extracellular loop that define charge selectivity 
(Van Itallie et al., 2001; Colegio et al., 2002), other structural 
features that determine functional differences between claudins 
remain  to  be  discovered. These  may  include  extracellular   
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monolayers ranged from 151 ± 6 to 255 ± 5 Ohms x cm
2. All data shown 
are representative of ≥3 experiments, each in triplicate or greater. For   
stable transfectants, data are representative of ≥3 stable cell lines for each 
construct, each assayed in triplicate.
NaCl dilution potentials were measured similarly and ion selectivity 
was determined as described previously (Weber et al., 2010). Biionic po-
tentials were measured by replacing basal Na, which has a radius of 0.95 Å, 
for organic cations with larger radii, specifically methylamine (1.9 Å), 
ethylamine (2.3 Å), tetramethylammonium (2.8 Å), tetraethylammonium 
(3.3 Å), or N-methyl-d-glucamine (3.7 Å) (Sigma-Aldrich). Absolute Na
+ 
permeability (PNa) was calculated using the equation
P
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F
G
P
P
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CL
NA
Cl
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where G is the overall monolayer conductance per unit surface area mea-
sured in symmetrical HBSS solutions, T is the absolute temperature, R is the 
gas constant, and F is Faraday’s constant (Kimizuka and Koketsu, 1964; 
Yu et al., 2009). From the value of PNa, and the known relative permeabili-
ties to the other ions, the absolute permeabilities to those ions could then 
be deduced using the Goldman-Hodgkin-Katz equation. Liquid junction po-
tentials, measured using cell-free Transwells, were <0.1 mV. All data shown 
are representative of ≥3 experiments, each in triplicate.
For flux of larger macromolecules, FITC (0.1 mg/ml), 3-kD FITC-
dextran (1 mg/ml), and 10-kD FITC-dextran (2.5 mg/ml) conjugates (Invit-
rogen) were added to the apical chamber. Aliquots were removed from the 
basal chamber at 30-min intervals over 2 h, as described previously (Wang 
et al., 2005). All data shown are representative of ≥3 experiments, each 
in triplicate.
Gene knockdown
For  transient  CK2  knockdown,  Caco-2BBe  cells  were  cotransfected  with 
pooled CK2 (5-GCAUUUAGGUGGAGACUUC-3, 5-GGAAGUGUC-
UUAGUUAC-3, 5-GCUGGUCGCUUACAUCACU-3, and 5-AACAUU-
GUCUGUACAGGUU-3) and CK2’ (5-GAGUUUGGGCUGUAUGUUA-3, 
5-GGGACAACAUUCACGGAAA-3,  5-GAUAGAUCACCAACAGAAA-3, 
and 5-UUAAGCAACUCUACCAGAU-3) targeting siRNA (Thermo Fisher 
Scientific).  Transient  claudin-1  knockdown  used  pooled  claudin-1   
(5-GAGGAUGGCUGUCAUUGGG-3,  5-CACCAAGGCCCUAUC-
CAAA-3, 5-GGAAAGACUACGUGUGACA-3, and 5-GCAAUAG-
AAUCGUUCAAGA-3)  targeting  siRNA  (Thermo  Fisher  Scientific).  All 
siRNA species were transfected using Lipfectamine 2000 (Invitrogen), as 
described previously (Hu et al., 2006), and controls were transfected with 
nontargeting pooled scrambled siRNAs with similar GC content. Monolayers 
were studied 7 d after confluence.
pSUPER (Oligoengine) containing the occludin targeting sequence 
5-GTGAAGAGTACATGGCTGC-3 (Yu et al., 2005) was used to stably 
transfect Caco-2BBe cells stably expressing SGLT1 (Turner et al., 1997), 
which suppressed >90% of occludin expression. ZO-1 knockdown cells 
were generated similarly, as described previously (Yu et al., 2010). Claudin-2 
knockdown was achieved by stably transfecting Caco-2BBe with pSUPER 
vector containing the targeting sequence 5-GCTAAGGGCTATAGACAAT-3. 
Controls for each were stably transfected with a pSUPER vector containing 
a related, but ineffective, sequence.
CK2 assay
CK2 activity was assessed in lysates of siRNA-treated Caco-2 cells as de-
scribed previously (Ruzzene et al., 2010). In brief, 300 µg total cell protein 
was incubated with 0.1 mM CK2 substrate peptide (RRRADDSDDDDD) 
and 10 µM [
32P]ATP for 10 min at 30°C in a total volume of 20 µl. Reac-
tions were terminated by spotting onto phosphocellulose filters, which were 
then washed with 0.5% phosphoric acid. Because other kinases can phos-
phorylate the substrate peptide, all samples were assayed in the presence 
of vehicle or 0.5 µM TBCA; the TBCA-inhibitable activity was considered 
to represent CK2 activity.
Immunoblots
Caco-2BBe monolayers were scraped from Transwell supports and mouse 
jejunal enterocytes were isolated as described previously (Clayburgh et al., 
2005; Raleigh et al., 2010). Cells were resuspended and lysed in reducing 
Laemmli sample buffer, and protein concentrations were determined. Equal 
quantities of protein were loaded into each lane for SDS-PAGE separation.   
Immunoblots were performed as described previously (Raleigh et al., 2010),   
Potential therapeutic utility  
of CK2 inhibition and occludin  
S408 dephosphorylation
Our observation that occludin regulates paracellular pore func-
tion by a mechanism that is, primarily, dependent on claudin-2, 
together with the near complete absence of claudin-2 expres-
sion in adult mouse intestine (Holmes et al., 2006), is consistent 
with essentially normal intestinal Na
+ conductance and epithe-
lial resistance reported in adult occludin knockout (Saitou et al., 
2000; Schulzke et al., 2005) and adult, but not neonatal, claudin-2 
knockout mice (Tamura et al., 2011). In addition, these data fit 
with the observations that CK2 inhibition reduces EGFP-occludin 
mobile fraction but does not affect paracellular flux of BSA, a 
leak pathway probe, or water in vivo. However, claudin-2 ex-
pression is known to be induced by mucosal immune activation in 
mice (Weber et al., 2010) and in human and experimental inflam-
matory bowel disease (Heller et al., 2005; Prasad et al., 2005; 
Zeissig et al., 2007; Weber et al., 2008, 2010). Our data show that, 
in this situation, CK2 inhibition reverses claudin-2–dependent in-
creases in paracellular cation flux induced by IL-13, a key path-
ological mediator (Heller et al., 2002, 2005). Thus, although 
regulation of occludin S408 phosphorylation is not understood 
and would benefit from development of detection reagents, such 
as phosphospecific antibodies, it is tempting to speculate that 
CK2 inhibitors, several of which are being considered for clini-
cal trials (Bortolato et al., 2008; Siddiqui-Jain et al., 2010), may 
be of therapeutic use in inflammatory bowel disease.
In conclusion, these data demonstrate that occludin S408 
phosphorylation by CK2 acts as a molecular switch that regu-
lates TJ protein interactions, molecular dynamics, and barrier 
function. In the absence of CK2 activity, occludin, ZO-1, and 
claudin-2 form a stable complex at the TJ. By phosphorylating 
S408, CK2 dissociates these proteins and facilitates cation flux 
across claudin-2–based pores. These results provide a new frame-
work to understand the molecular interactions that regulate the 
TJ barrier in health and disease.
Materials and methods
Cell culture
Caco-2BBe cells were maintained in DME (4.5 g glucose/l) with 10% FCS 
and 15 mM Hepes, pH 7.4. Subconfluent, rapidly growing cultures were 
trypsinized and plated at confluence on collagen-coated, 0.4-µm pore size, 
polycarbonate membrane Transwells (Corning). Media was replenished 
thrice weekly, and monolayers were studied 14 d after confluence, unless 
otherwise specified (Turner et al., 1997). T84 cells were maintained in 1:1 
F12/RPMI1640 media supplemented with 10% newborn calf serum and 
15 mM Hepes, pH 7.4, as described previously (Weber et al., 2010). 
These were plated at confluence on Transwell membranes and studied after 
10 d. CK2 inhibitors used were 4,5,6,7-tetrabromobenzotriazole (Sigma-
Aldrich),  2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole  (Sigma-
Aldrich), and tetrabromocinnamic acid (EMD). All CK2 inhibitor stocks 
were made in DMSO. DMAT became unavailable and was replaced by 
TBCA in the course of this work. CK2 inhibitors and S3226 (Aventis 
Pharma)  were  added  to  both  apical  and  basolateral  media  (Schwark   
et al., 1998). PIK was applied apically (Zolotarevsky et al., 2002).   
IL-13 (R&D Systems) was added basally as described previously (Weber   
et al., 2010).
Electrophysiology and barrier function
A standard current clamp (University of Iowa Bioengineering, Iowa City, IA) 
was  used  to  measure  transepithelial  resistance  (TER)  of  cultured  mono-
layers, as described previously (Turner et al., 1997). TER of control Caco-2 579 Occludin S408 regulates epithelial barrier function • Raleigh et al.
exposed, cannulated, and flushed to remove luminal material. The jejunum 
was perfused with media containing DMAT or vehicle for 60 min before 
imaging as described previously (Marchiando et al., 2010). A similar ap-
proach was used to assess paracellular Alexa 488 BSA and water flux   
in vivo (Clayburgh et al., 2005; Marchiando et al., 2010).
GST pulldown
GST-occludin 383–522 wild-type, S408D, and S408A constructs were 
generated by site-directed mutagenesis of previously described GST-occludin 
C-terminal tail constructs (Raleigh et al., 2010). A VSV G epitope-tagged 
human ZO-1 U5-GuK domain construct consisting of residues 591–754 
was generated by cloning cDNA into pGEX-4T3 (GE Healthcare) and re-
moving the GST coding sequence by site-directed mutagenesis (Raleigh et al., 
2010). BL21(DE3)pLysS-competent bacteria were transformed with GST- 
and VSV G–tagged constructs, induced with IPTG, and processed using a 
GST Protein Interaction Pulldown kit (Thermo Fisher Scientific) with RIPA 
buffer  containing  TBS,  1%  Nonidet  P-40,  0.5%  sodium  deoxycholate, 
0.1% SDS, 0.004% sodium azide, and protease and phosphatase inhibi-
tors (Santa Cruz Biotechnology, Inc.). For pulldown from Caco-2BBe lysates, 
monolayers were washed once in 4°C TBS and incubated in RIPA buffer at 
4°C for 30 min. Cells were passed five times through a 21-gauge needle, 
and clarified for 5 min at 12,000 rpm. Bacterial and Caco-2BBe superna-
tants were incubated with immobilized bait constructs at 4°C overnight 
with rocking, and, after three washes in 10 mM NaCl, eluted with 10 mM 
reduced glutathione. All data shown are representative of ≥2 experiments, 
each with at least duplicate samples.
Statistical analysis
All data are presented as mean ± SE unless otherwise specified. Student’s 
unpaired t test was used to compare means, with statistical significance 
taken as P < 0.05.
Online supplemental material
Fig. S1 shows that neither CK2 inhibition nor CK2 knockdown affect TJ 
protein expression, provides controls for CK2 knockdown, demonstrates 
that CK2 effects on NHE3 function do not play a role in the observed bar-
rier regulation, assesses paracellular flux of larger uncharged molecules 
before and after CK2 inhibition, and evaluates intracellular CK2 distribu-
tion. Fig. S2 shows kymographs of EGFP-occludin in control and CK2 
knockdown Caco-2 monolayers, images and kymographs of EGFP-occludin   
in mouse jejunal enterocytes in vivo, that CK2 inhibition does not affect TJ 
protein expression in mouse jejunal enterocytes, and that CK2 inhibition 
does not affect in vivo water transport or paracellular BSA flux in mouse 
jejunum. Fig. S3 shows redistribution of wild-type and mutant EGFP-occludin 
proteins in response to CK2 inhibition and provides protein expression 
and transepithelial resistance data for transfected Caco-2 monolayers.   
Fig. S4 shows protein expression after ZO-1, claudin-1, or claudin-2 knock-
down,  cation  permeability  of  stable  claudin-2  knockdown  Caco-2  cell 
lines, and the TER response of claudin-2 knockdown cell lines to myosin 
light chain kinase inhibition. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.201010065/DC1.
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